X0609 4 2026-06-17 0001815442 Kymera Therapeutics, Inc. KYMR 0001451612 Booth Bruce false C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, FLOOR 4 WATERTOWN MA 02472 true false false false 1 Common Stock 2026-06-17 4 M 0 11741 20 A 11741 D Common Stock 2026-06-17 4 S 0 11741 89.98 D 0 D Common Stock 2026-06-17 4 S 0 92169 90.38 D 3807660 I See footnote Common Stock 2026-06-17 4 S 0 12902 90.38 D 662042 I See footnote Common Stock 2026-06-18 4 S 0 62897 90.48 D 3744763 I See footnote Common Stock 2026-06-18 4 S 0 32359 91.85 D 3712404 I See footnote Common Stock 2026-06-18 4 S 0 5672 92.16 D 3706732 I See footnote Common Stock 2026-06-18 4 S 0 8809 90.48 D 653233 I See footnote Common Stock 2026-06-18 4 S 0 4526 91.85 D 648707 I See footnote Common Stock 2026-06-18 4 S 0 793 92.16 D 647914 I See footnote Common Stock 2026-06-22 4 S 0 14921 92.14 D 3691811 I See footnote Common Stock 2026-06-22 4 S 0 2035 94.48 D 3689776 I See footnote Common Stock 2026-06-22 4 S 0 11783 95.12 D 3677993 I See footnote Common Stock 2026-06-22 4 S 0 20903 96.24 D 3657090 I See footnote Common Stock 2026-06-22 4 S 0 16084 97.68 D 3641006 I See footnote Common Stock 2026-06-22 4 S 0 25976 98.58 D 3615030 I See footnote Common Stock 2026-06-22 4 S 0 52442 99.57 D 3562588 I See footnote Common Stock 2026-06-22 4 S 0 56348 100.17 D 3506240 I See footnote Common Stock 2026-06-22 4 S 0 6597 101.61 D 3499643 I See footnote Common Stock 2026-06-22 4 S 0 8990 102.48 D 3490653 I See footnote Common Stock 2026-06-22 4 S 0 2179 92.14 D 645735 I See footnote Common Stock 2026-06-22 4 S 0 286 94.48 D 645449 I See footnote Common Stock 2026-06-22 4 S 0 1648 95.12 D 643801 I See footnote Common Stock 2026-06-22 4 S 0 2919 96.24 D 640882 I See footnote Common Stock 2026-06-22 4 S 0 2247 97.68 D 638635 I See footnote Common Stock 2026-06-22 4 S 0 3603 98.58 D 635032 I See footnote Common Stock 2026-06-22 4 S 0 7319 99.57 D 627713 I See footnote Common Stock 2026-06-22 4 S 0 7879 100.17 D 619834 I See footnote Common Stock 2026-06-22 4 S 0 918 101.61 D 618916 I See footnote Common Stock 2026-06-22 4 S 0 1253 102.48 D 617663 I See footnote Stock Option (Right to Buy) 20 2026-06-17 4 M 0 11741 0 D 2030-08-19 Common Stock 11741 28127 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) and (7) through (19). This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.03 inclusive. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.04 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.10 to $92.085 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.1191 to $92.2833 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.11 to $92.50 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.93 to $94.91 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.99 to $95.76 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.959 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.0018 to $97.99 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.00 to $98.9997 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.9942 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.8925 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.98 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.01 to $103.00 inclusive. Fully vested and exercisable. Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings. /s/ Ommer Chohan, Attorney-in-Fact 2026-06-22